Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...

The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the ...

In a time when COAs are more nuanced, critical and complex than ever, researchers can turn to best practices to move forward ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got less crowded and Amgen and Lilly struck startup deals.